Overview
To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions
Status:
Completed
Completed
Trial end date:
2005-04-01
2005-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fasting conditions.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
SandozTreatments:
Cefdinir
Cephalosporins
Criteria
Inclusion Criteria:- No clinically significant abnormal finding on physical exam, medical history, or
clinical laboratory results on screening.
Exclusion Criteria:
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.